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Abstract Although long-acting inhaled b2-agonists improve various outcome measures in COPD, no double-blind
studyhas yet shown a significanteffectof these drugs on exercise capacity. In a randomized, double-blind, placebo-con-
trolled, crossover study, patients received formoterol (4.5,9, or18 mgb.i.d. viaTurbuhalers), ipratropiumbromide (80 mg
t.i.d. via pMDIwith spacer), or placebo for1week.Main endpoint was time to exhaustion (TTE) in an incremental cycle
ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events.
Thirty-four patientswith COPDwere included, mean age 64.8 years,FEV155.6% predicted, reversibility 6.1% predicted.
All doses of formoterol, and ipratropium significantly improved TTE,FEV1,FEF25-75%,FRC,IVC,RVand sGAWcompared
with placebo. A negative dose--response relationship was observed with formoterol. Ipratropium increased time to
exhaustion more compared with formoterol,18 mg, but not with formoterol, 4.5 and 9 mg. No changes in Borg score
were found.Therewasno difference inthe adverse eventprofile betweentreatments.In conclusion,1weekoftreatment
with formoterol and ipratropium significantly improved exercise capacity and lung function compared with
placebo. However, a negative dose--response relation for formoterol was unexpected and needs further
investigation.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2001.1335, available online athttp://www.idealibrary.comon
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Dyspnoea on exertion is an important feature of chronic
obstructivepulmonarydisease (COPD).Bronchodilators
are routinely prescribed to symptomatic patients with
COPD with the aim of reducing bronchial obstruction
and symptoms and improving exercise capacity. In the
GOLD guidelines on COPD (1), bronchodilators are re-
commended either as needed or on a regular basis to
preventor reduce symptoms.Theguidelines suggest that
long-acting inhaled bronchodilators are themost conve-
nient therapy, and some studies have suggested that in-
haled long-acting b2-agonists are more e¡ective thanReceived11February 2002, accepted is revised form 4 March 2002.
Correspondence should be addressed to: H.A.M.Kerstjens,MD, PhD,
Department of Pulmonary Diseases,University Hospital Groningen,
Hanzeplein1,9713 GZGroningen,The Netherlands.Fax:+3150 3 6193
20; E-mail: h.a.m.kerstjens@int.azg.nlanticholinergics in improving lung function in patients
with stable COPD (2,3). However, the e¡ects of long-
acting b2-agonists on exercise capacity in COPD have
not been intensively investigated.There have been three
double-blind studies investigating the e¡ects on exercise
capacity of salmeterol (4--6), but there are no published
reports about the e¡ects of formoterol on exercise ca-
pacity in COPD.
We investigated the e¡ects of 1 week maintenance
treatment with three di¡erent doses of formoterol fu-
marate dihydrate (4.5, 9, and18mg b.i.d) viaTurbuhalers,
ipratropium (80mg t.i.d.) via pMDI and spacer, and place-
bo on exercise capacity, Borg dyspnoea score and lung
function in patients with COPD.We hypothesized that
formoterol would give a dose-dependent increase in ex-
ercise time, signi¢cantly greater than with placebo and
similar to that with ipratropium. The primary e⁄cacy
outcomevariablewas time to exhaustion (TTE), de¢ned
560 RESPIRATORYMEDICINEas the total cycling time during an incremental bicycle
ergometer test. Secondary outcomevariables were lung
function parameters assessed before the exercise test
and dyspnoea (measured by Borg score) while cycling.
PATIENTSANDMETHODS
Study design
Four centres participated in this randomized, double-
blind, placebo-controlled, crossover study, comprising
¢ve1-week study periods, each separated by a 6--12 day
wash-out period. During the wash-out period, patients
were allowed to use only terbutaline sulphate (500mg/
dose, Bricanyls Turbuhalers, AstraZeneca Pharmaceu-
tical Productions, Sweden) on demand. In the study
week, they used one of the following study medications
for exactly 7 days: formoterol fumarate dihydrate (deliv-
ered dose of 4.5mg, 9, or18mg b.i.d., corresponding to 6,
12, and 24mg metered dose, OxissTurbuhalers, Astra-
Zeneca Pharmaceutical Productions), ipratropium bro-
mide (80mg t.i.d. Atrovents aerosol, Boehringer
Ingelheim, Germany) inhaled via a spacer (Aerocham-
bers, Boehringer Ingelheim,Germany), or placebo, em-
ploying a double-dummy technique. The protocol was
approved by the Medical Ethics Committee at each cen-
tre and all patients gavewritten informed consent.
Patients
Inclusion criteria: Patients in a stablephase of COPDwere
enrolled.Men or women aged50 yearswere enrolled if
they had a clinical diagnosis of COPD,with symptoms for
at least the past 2 years. All patientswere current or ex-
smokers with a smoking history of at least10 pack-years.
After a run-in period of 6--12 days (visit 2), in which no
bronchodilator medication except terbutaline was al-
lowed, thepre-bronchodilator forced expiratoryvolume
in one second (FEV1) was established.This had to be 40--
70%predicted and 40.7 l. Also, the FEV1 /FVC ratio
had to be o88% predicted for men and o89% for
women (7).
Exclusion criteria: Patients having diseases other than
COPD limiting their performance in an exercise test
were excluded. Also excluded were patients with a his-
tory of asthma or seasonal allergic rhinitis with a disease
onset before 40 years of age, or other respiratory dis-
eases which might have in£uenced the results of the
study. Patients experiencing an exacerbation of their
COPD requiring oral corticosteroids or antibiotics 30
days prior to enrollment, or those using oxygen therapy
at home, were also excluded. Patients were withdrawn
from the study if they experienced more than one ex-
acerbation requiring oral corticosteroids or antibiotics
during the study.Medication at enrollment andduring the
study
Patients were not allowed to use b-blockers (including
eyedrops), antihistamines, leukotriene antagonists, or
medication containingephedrine. Inhaledororal steroids
had to be kept at a constant dosage from at least 30 days
prior to enrollment and during the study. The highest
allowed daily dose of oral corticosteroids was 10mg
prednisolone, 8mg methylprednisolone, or 1mg beta-
methasone. Mucolytics had to be kept constant 14 days
prior to visit 1. Patients were allowed to use terbutaline
as rescue medication in the treatment and wash-out
periods.
Study protocol
Atvisit1, participants underwent a physical examination,
blood and urine analyses, electrocardiography, and per-
formed a progressive cycle ergometry (PCE) test for
practice purposes. At visit 2, after a run-in period of 6--
12 days, baseline spirometry and body plethysmography
were donewithpre-bronchodilator.Reversibility was as-
sessed15min after administration of inhaled terbutaline
sulphate, 1mg, and was calculated as the di¡erence be-
tween pre- and post-bronchodilator FEV1 % predicted
(8).This was followed by a second PCE for practice pur-
pose. Patients were then randomized and began using
the study medication for the ¢rst period. Patients at-
tended the outpatient clinic once every 2 weeks (visits
3--7) at the same time of the day (within1h). Studymed-
ication was taken at home 2--3 h before the spirometry
tests. Spirometry and body plethysmography were per-
formed at each visit, followedby a PCE test.
MEASUREMENTS
Spirometry
No rescue medication was allowed within 6h prior to
measurements. Spirometry was performed according
to the guidelines of the ERS (7). After15min of rest, the
patients performed three acceptable forced expiratory
measurements, sitting in anuprightposition andwearing
a nose-clip. The highest FEV1, FVC and inspiratory vital
capacity (IVC) were taken. The forced expiratory £ow
between 25 and 75% of vital capacity (FEF25-75%) was de-
rived from the manoeuvre that gave the largest sum of
FVC and FEV1. Predicted values were calculated accord-
ing to the European Community for Steel and Coal, as
described by Quanjer (7).
Body plethysmography
After 1min of quiet breathing, lung volumes (total lung
capacity [TLC], residual volume [RV], and functional re-
TABLE 1. Baseline characteristics
Variable Mean (SD)
Age (Years) 64.8 (8.4)
FEV1 (l) 1.69 (0.47)
FEV1 (% pred) 55.6 (8.9)
IVC (l) 3.55 (0.96)
FEV1/ IVC (%) 47.5 (7.3)
FEV1/IVC (% pred) 62.9 (9.8)
FVC (l) 3.51 (1.00)
FEV1reversibility (l) 0.19 (0.15)
FEV1reversibility (% pred) 6.1 (4.42)
Smokinghistory N (%)
Past-smoker 21 (62)








FEV1 = forcedexpiratory volumein1sec.FVC= forced
vital capacity; IVC = inspiratory vital capacity, SD = stan-
dard deviation.
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measured. Raw was obtained at inspiratory and expira-
tory £ows of 0.5 l/s at a respiration rate of 0.5Hz.Means
of three measurements were recorded. Speci¢c airway
conductance (sGAW) was calculated on the basis of
these values.
Progressive cycle ergometer (PCE) test
The symptom-limited maximum exercise test was per-
formed on an electronically braked bicycle ergometer.
Patients cycled at a rate of 60 rpm, starting at 10W for
1min and increasing by10W each minute. Patients were
asked to cycle as long as possible until limited by dys-
pnoea or exhaustion. PCE tests performed at visits 1
and 2were for trainingpurposes only, tominimize learn-
ing e¡ects.TTEwasmeasuredwith a stopwatch as being
the time from the start of exercise to the moment pa-
tients were unable to cycle any longer (maintaining
60 rpm). Borg dyspnoea scores (9) were performed at
baseline, every 2minwhile cycling, andwhen the patient
stopped cycling.
Treatment compliance
Atenrollment, patientswere carefully instructedhow to
use both the Turbuhalers inhaler and the pMDI with
Aerochambers to ensure the correct inhalation techni-
que. During each visit, inhalation techniques were veri-
¢ed using empty inhalers.
During each period, patients kept track of theirmedi-
cation use in a diary.The investigator checked the diary
for completeness at each clinic visit.
STATISTICS
Descriptive data are presented as means and standard
deviations (SD). Outcome variables were analysed with
analysis of variance (ANOVA) using patient, treatment,
and period as covariates. The results are shown as ad-
justed means and standard errors of the mean (SEM) as
derived from the ANOVA model. A P-value of o0.05
was considered statistically signi¢cant. Laboratory re-
sults, bloodpressure and ECGwere obtained at the ¢rst
and last visit for safety reasons only. Since patients re-
ceived one of ¢ve di¡erent treatments immediately be-
fore the last visit, results were not analysed statistically.
RESULTS
Patient characteristics
Forty-seven patients were enrolled in the study. Twelve
subjects did not meet the selection criteria at visit 2,
thus 35 patients were randomized to treatment.Two ofthe 35 patients did not complete the study; one patient
discontinued because of a trauma to the right arm (this
patientmissedoneperiod andwas includedin the results
for the other four treatment periods) and one patient
was erroneously included. Four patients deviated from
the protocol and did not follow the randomized treat-
ment order, one because of an exacerbation and three
because of missed dose(s) of medication 24h prior to a
visit. The faulty periods were repeated directly after
study period 5 and the faulty study period was ignored
in the analyses. The data from 34 patients were used in
the statistical analyses. Baseline characteristics of these
patients are displayed inTable1.
Progressive cycle ergometer test (PCE test)
The three doses of formoterol and ipratropium 80mg
t.i.d. increased TTE signi¢cantly compared with placebo
(Table 2). The mean increases in TTE with formoterol
4.5mg,9mg,18mg and ipratropium comparedwith place-
bo were 0.73, 0.57, 0.38 and 0.77 (SEM. 0.17)min, respec-
tively. Though all doses of formoterol were signi¢cantly
better than placebo, there was a negative dose--re-
sponse relationship for the three doses of formoterol,
the lowest dose corresponding to the longest exercise
time.TheTTE with ipratropium was signi¢cantly longer
(P=0.02) thanwith formoterol18mg, but not longer than
with either formoterol 4.5 or 9mg (Table 2).
TABLE 2. E¡ects of treatmenton exercise capacity (meanbicycle exercise time) and Borg score
Treatment Time to exhaustion
(min)
Borgdyspnoea score
Formoterol 4.5 mg b.i.d. 10.94*** 7.61
Formoterol 9 mgb.i.d. 10.78** 7.64
Formoterol18 mg b.i.d. 10.59*, w 7.41
Ipratropium 80 mg t.i.d. 10.98*** 7.64
Placebo 10.21 7.64
s.e.m. (ANOVA)z 0.12 0.45
All data are period-adjustedmeans after1weekoftreatment.
*Po0.05, **Po0.01, and ***Po0.0001comparedwith placebotreatment,
wPo0.05 comparedwith ipratropium; SEM = standard errorof themean.
zSee Methods forexplanation of single SEM).
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There were no signi¢cant di¡erences in end-exercise
Borg dyspnoea scores between the di¡erent treatments
(Table 2).Nor were there di¡erences in themean values
of dyspnoea, calculated as the area under the Borg dys-
pnoea score curve during exercise divided by the total
exercise time, as a measure of the mean experienced
dyspnoea.
Lung function
All doses of formoterol and ipratropium signi¢cantly im-
proved FEV1 (Po0.0001) compared with placebo (Table
3).Themean increase in FEV1with formoterol 4.5,9,18mg
and ipratropium compared with placebo was 0.19, 0.24,
0.38 and 0.20 (SEM 0.04) l, respectively. FVC, IVC, FRC,
SGAW and RValso improved signi¢cantly for all doses of
formoterol and ipratropium compared with placebo.
Although there was a trend for a greater improvement
in FEV1 and sGAW with 9 and 18mg formoterolTABLE 3. Lung function parameters during treatment with fo
placebo
Treatment FEV1 (l) IVC (l) FVC (l) FEF
Formoterol 4.5 mg b.i.d. 1.80**** 3.81**** 3.68 0
Formoterol 9 mgb.i.d. 1.85**** 3.77**** 3.73 0
Formoterol18 mg b.i.d. 1.87**** 3.81**** 3.73 0
Ipratropium 80 mg t.i.d. 1.81**** 3.82**** 3.74 0
Placebo 1.61 3.5 3.45 0
SEM
z (ANOVA) 0.04 0.05 0.05 0
All data are period-adjustedmeans after1weekoftreatment.
FEV1 =forced expiratory volume in one second,IVC = inspirator
expiratory £owbetween 25 and 75%of vitalcapacity; sGAW=s
RV=residualvolume,TLC= totallungcapacity; SEM= standarder
forexplanation of single s.e.m.). ****Po0.0001, ***Po0.001, **comparedwith 4.5mg, these trendswerenot statistically
signi¢cant. There were no signi¢cant di¡erences be-
tween ipratropium and the three doses of formoterol in
any of these lung function parameters. FEF25-75%
improved signi¢cantly compared with placebo with all
three doses of formoterol (Po0.05), but not with
ipratropium (P=0.23).
SAFETY
There were two adverse events categorized as serious.
One patient, while in the wash-out period after formo-
terol 9mg, developed acute glaucoma; another patient,
while on ipratropium, injured her arm in an accident
and missed the last visit. Neither serious adverse event
was deemed related to the investigational products.
There was no signi¢cant di¡erence between the treat-
ments in the number or pro¢le of adverse events. The
number of side-e¡ects commonly associated with b2-
agonists (headache, palpitation, tremor, etc.) was low inrmoterol 4.5, 9, and 18 mg b.i.d., ipratropium 80 mg t.i.d., and
25-75% (l) sGAW ((skPa)
1) FRC (l) RV (l) TLC (l)
.62* 0.82**** 4.81** 3.55*** 7.25
.66*** 0.81**** 4.73*** 3.36**** 7.06
.66*** 0.79**** 4.77** 3.45*** 7.20
.59 0.82**** 4.78** 3.43*** 7.12
.56 0.54 5.07 3.81 7.19
.03 0.04 0.09 0.10 0.09
y vital capacity,FVC = forced vital capacity,FEF25-75% =forced
peci¢c airwayconductance,FRC= functionalresidualcapacity,
rorofthemeanofANOVA (Analysisof variance,z seeMethods
Po0.01and *Po0.05 comparedwith placebotreatment.
TABLE 4. Heart rates
Treatment Heart rate before exercise Increase inheart rate afterexercise
Formoterol 4.5 mg b.i.d. 77.4 (12.5) 50.5 (21.9)
Formoterol 9 mgb.i.d. 80.1 (17.5) 46.6 (17.9)
Formoterol18 mgb.i.d. 79.9(15.3) 47.4 (21.0)
Ipratropium 80 mg t.i.d. 78.3 (13.8) 48.8 (18.6)
Placebo 79.1 (18.8) 47.3 (22.7)
Data are presented asmeans (SD).
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ported by only one patient, using formoterol18mg b.i.d.
No signi¢cant di¡erences were noted in heart rates be-
fore or after exercise in any of the treatment groups
comparedwithplacebo (Table 4). All doses of formoterol
werewell tolerated.
DISCUSSION
Formoterol 4.5,9,18mgb.i.d., and ipratropium80mg t.i.d.
all gave signi¢cant improvements in exercise capacity and
lung function compared with placebo without a signi¢-
cant change in Borg dyspnoea score. There was a nega-
tive dose--response relationship for the three doses of
formoterol, the lowest dose of formoterol correspond-
ing to the longest exercise time.
We found a small, but signi¢cant, improvement of
0.73min for formoterol 4.5mg in an incremental cycle
ergometer test. Even though signi¢cantly di¡erent from
placebo, intuitively, this result seems a very small di¡er-
ence.Unfortunately, there are no data de¢ning themini-
mal clinically sign¢cant improvement in the incremental
cycle ergometer test.Our study was designed some time
ago, and many authors would currently advocate an en-
durance test at sub-maximal exercise level (10 --11).Only a
few studieshave actually compared the di¡erentexercise
modes with bronchodilator interventions. Such a study
was performed by Oga et al. in which oxitropium was
found to yield signi¢cant improvements in a 6-min walk-
ing test, a progressive cycle ergometer test, and a cycle
endurance test at 80% of maximal workload (11).The 7%
improvement we found in the progressive cycle erg-
ometer test is at least as good as the 3.5% improvement
found in their study (which corresponded to a 19% im-
provement in endurance time (11).Our result would, by
extrapolation, be expected to translate to similar im-
provements in endurance time as those foundbyO’Don-
nell (10). Therefore, the relatively small improvement in
our study was not only signi¢cant, but also within the
ranges found by others to be clinically relevant.
To the best of our knowledge, this is the ¢rst double-
blind study to demonstrate an increase in exercise capa-
city with long-acting b2-agonists in patients with COPD.Boyd and colleagues (5) investigated the e¡ects of salme-
terol 50 and100mg b.i.d. for16 weeks on symptoms, lung
function and exercise capacity with a 6-min walking dis-
tance test.They found no improvement in exercise capa-
city for either of the doses of salmeterol.Grove et al. (4)
evaluated the e¡ect of salmeterol 50mg b.i.d. for 4
weeks, and also foundno e¡ect in the 6-minwalking dis-
tance test or in adaptation capacity measuredwith a cy-
cle-ergometer test.Mahleretal. (6) compared treatment
with salmeterol 50mg b.i.d for12 weeks vs placebo, again
without a signi¢cantdi¡erence in the 6-minwalking test.
These studies and the present one di¡er in a number
of aspects. Firstly, the patients in the present study had
less severe airway obstruction, i.e. a mean FEV1 of 1.69 l
comparedwith1.28,1.17 and1.29 l in the studies by Boyd,
Grove, and Mahler, respectively. Patients with reversibil-
ity of airwayobstructionwere excluded from the studies
by Boyd et al. (5) and Grove et al. (4), in contrast to our
study.Nine out of the 34 patients in our study had a sig-
ni¢cantreversibility to a short-acting b2-agonist, de¢ned
as an FEV1 increment of 9% of the predicted normal va-
lue. However, all results remained signi¢cant when we
re-analysed our data without the nine subjects with sig-
ni¢cantreversibility.Furthermore,weused an incremen-
tal cycle ergometer test, whereas Boyd, Grove, and
Mahler used the 6-min walking distance test to deter-
mine exercise capacity.The 6-min walking distance test
is self-paced, time-limited, tests at sub-maximal load,
and has no incremental resistance, unlike an incremental
cycle-ergometer test , which testsmaximal load and ex-
ercise time. Thus, the cycle ergometer measures other
aspects of exercise. Many studies with short-acting b2-
agonists have used the 6- and12-minwalking tests (4,12--
20). Approximately, half of these studies found a signi¢-
cant increase in exercise capacity after b2-agonist use,
with the suggestion of more signi¢cant results when
using the12min rather than the 6-min walking distance
test. As an additional test,Grove et al. used a cycle test,
with physiological strain as the outcome variable (4);
maximal exercise capacity was estimated from sub-max-
imal exercise data, according to the theory of the adap-
tation capacity (21). However, this extrapolated maximal
exercise capacity is di⁄cult to compare with our
























FIG. 1. Individual dose response curves (n=34) for time to ex-
haustionwiththree doses of formoterol (4.5,9, and18 mgb.i.d.).
564 RESPIRATORYMEDICINEdi¡erence in results could be due to the long-acting b2-
agonist used, since the negative studies used salmeterol,
which is a partial agonist, whereas we used the full ago-
nist formoterol.The di¡erence between a full and a par-
tial agonist could theoretically be important in a
situation with high endogenous catecholamine levels
such as during exercise (although our results provide no
proof for this since we tested formoterol only). Finally,
Patakas et al. (22) performed a single-blind study, with a
single dose of 50mg of salmeterol in patients with an
FEV1 less than 1l, ¢nding a signi¢cant improvement in
walking distance at themaximal Borg dyspnoea score.
Thenegative dose--responserelationship for the three
doses of formoterol was an unexpected ¢nding, which
was not re£ected in a negative dose--response in lung
function parameters (which, in fact, showed a positive
dose--response relationship). There are both intra- and
extra-pulmonary explanations that could account for
this.
An intra-pulmonary explanation could be a dose-de-
pendent deterioration in the existing ventilation--perfu-
sion mismatch in COPD, due to dose-dependent
vasodilation caused by b2-stimulation of the pulmonary
vasculature (23) in combination with bronchodilation.
An increasing mismatch at higher doses of formoterol
couldbe responsible for a poorer increase in exercise ca-
pacity comparedwith lower formoterol doses.
Possible extra-pulmonary explanations for smaller ef-
fects on exercise capacity with higherdoses of formoter-
ol include an increase in side-e¡ects, especially tremor.
However, we did not observe a di¡erence in the number
or pro¢le of adverse events between the three doses of
formoterol, ipratropium and placebo. Tremor was re-
ported in only one patient receiving formoterol 18mg
b.i.d. Other known muscle e¡ects of b2-agonists are
those on skeletal muscle force. b2-agonists ‘muscle type’
in a dose dependent fashion increase the contraction
force of the fast-contracting muscle type, which is im-
portant for PCE. Holmberg and Waldeck (24) have de-
monstrated that, after maintenance treatment of guinea
pigs with terbutaline for less than1week, a marked tol-
erance develops for isoprenaline- or terbutaline-induced
increases in force generation of the fast-contracting
muscle type by transmural stimulation ex vivo (24). It can
be envisaged that such downregulation or uncoupling of
skeletal muscle b2-receptors also occurs after mainte-
nance formoterol treatment, in a dose-dependent fash-
ion, andmay lead to fewer functional b2-receptors being
available to endogenous catecholamines released during
exercise. Muscle performance may also be in£uenced by
the increase in serum lactate concentration induced by
b2-agonists (25).
All b2-agonists can have dose-dependent chronotro-
pic and inotropic e¡ects. These are considered to be
mediated predominantly via a direct e¡ect on cardiac
b2-receptors and via a re£ex mechanism, secondary toperipheral vasodilatation causedby stimulation of vascu-
lar b2-receptors.The chronotropic and inotropic e¡ects
of higher doses of b2-agonists suggest a potential for in-
creased myocardial oxygen consumption. However, we
found no signi¢cant di¡erence in heart frequencies pre-
or post-peakexercise for any treatments comparedwith
placebo. This result is in line with the ¢ndings of Grove
and Lipworth (26).Overall, the results suggest that pos-
sible negative e¡ects of formoterol on myocardial func-
tion in our study are too small to explain the negative
dose-response relationship. Finally, although the overall
dose--response relation was negative for the group as a
whole, it was certainly not invariably present, as indi-
cated by the individual dose--response curves presented
in Fig.1.
We analysed changes in Borg dyspnoea score during
exercise in several di¡erent ways and could not detect a
signi¢cantchangewith either formoterolor ipratropium.
This is in contrast to the studies by Grove (4) and Boyd
(5), but is in linewith the study by Mahler (6).
Our study con¢rms the signi¢cant e¡ects of
long-acting b2-agonists on lung function parameters in
COPD reported previously (4--6,27). Spirometric and
plethysmographic tests such as FEF25-75% and sGaw also
demonstrated signi¢cant improvements after all doses of
formoterol. Maesen et al. recently showed that this cor-
relates with a decreased work of breathing in patients
with apparently poorly reversible lung function (28). In
our study, we additionally found a signi¢cant reduction
in RV and FRC. The lowest dose of formoterol (4.5mg)
was su⁄cient for the greatest part of the e¡ect on lung
function parameters.
Ipratropium was given in a moderately high dose of
80mg t.i.d., and signi¢cantly improvedTTE andlung func-
tion parameters comparedwith placebo and to a similar
extent to formoterol 4.5mg. TTE with ipratropium was
signi¢cantly longer than with formoterol 18mg b.i.d. Re-
garding ipratropium and incremental exercise tests, only
single-dose studies have been performed so far (29--31).
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consumption at a PCE as outcome measures. The im-
provements found in the single dose studies are in line
with our results, after 1week of treatment. The signi¢-
cant but small improvements in exercise capacity with
formoterol and ipratropium are fully in line with other
studies testing bronchodilators with progressive cycle
ergometry in COPD (29,30,32,33).
In the present study, ipratropium at a moderately high
dose gave the same e¡ect as the lowdose of formoterol.
Thus, while ipratropium and the long-acting inhaled b2-
agonist formoterol can be used alternatively in patients
with moderate COPD, yielding similar improvement in
exercise capacity, this result is in line with the GOLD
guidelines suggesting that long-acting inhaledbronchodi-
lators aremore convenient (1).From our results we can-
not deduce whether treatment with formoterol and
ipratropium together wouldhave givenbetter responses
in lung function parameters and exercise capacity than
each treatment separately.
We conclude that formoterol signi¢cantly improves
exercise capacity and lung function in patients with
COPD.The e¡ects of low-dose formoterol (4.5mg b.i.d.)
are comparable to those of ipratropium 80mg t.i.d.The
¢nding of a negative dose--response relationship be-
tween formoterol and exercise time is unexpected and
needs further investigation.
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